>Mercado secundário de medicamentos para a hiperoxalúria da América do Norte, por tipo (Reloxaliase, diuréticos tiazídicos e suplementos), tipo de medicamento (prescrição e de venda livre), tipo de população (crianças e adultos), utilizador final (hospitais, clínicas especializadas, cuidados de saúde domiciliária e outros), Canal de distribuição (farmácias hospitalares, farmácias de retalho, farmácias online e outros), país (EUA, Canadá e México), tendências e previsão da indústria para 2028
Análise de mercado e insights: Mercado de medicamentos para a hiperoxalúria secundária da América do Norte
Espera-se que o mercado secundário de medicamentos para a hiperoxalúria ganhe crescimento de mercado no período de previsão de 2021 a 2028. A Data Bridge Market Research analisa que o mercado está a crescer com um CAGR de 67,3% no período de previsão de 2021 a 2028 e prevê-se que atinja os 8.346,46 milhões de USD até 2028. A perda de oxalobacter formigenes devido à elevada ingestão de antibióticos e à baixa consciência alimentar serão provavelmente os principais impulsionadores do mercado de medicamentos para a hiperoxalúria secundária.
Uma doença multifatorial que afeta diferentes órgãos e tecidos causada pela absorção de elevadas concentrações de oxalato devido a problemas intestinais é conhecida como hiperoxalúria secundária ou em fase extrema conhecida como hiperoxalúria entérica. Esta doença está altamente ligada à dieta e à má absorção provocada por alguma doença, uma vez que a ingestão de oxalato ou precursor de oxalato, como a vitamina C, está entre as principais causas da doença. A Oxalobacter formigenes, bactéria conhecida por ser o fator crítico para a hiperoxalúria secundária, utiliza o oxalato como elemento energético chave para completar a sua exigência funcional, desempenha um papel importante na ocorrência da doença.
Como medida preventiva, devem ser ingeridos alimentos com baixo teor de oxalato, mas em países com um estilo de vida socioeconómico altamente desenvolvido, como os EUA, a Europa e a China, os hábitos alimentares não são adequados e a falta de consciência alimentar é a principal causa da hiperoxalúria secundária, que se espera que impulsione o mercado secundário de medicamentos para a hiperoxalúria. A receita operacional é limitada no caso de hiperoxalúria secundária devido ao facto de um menor número de doentes-alvo levar a uma menor receita deste segmento operacional e espera-se que atue como restrição para o crescimento do mercado de medicamentos para a hiperoxalúria secundária. A dieta pobre em oxalato é difícil de manter, uma vez que as pessoas a consomem diretamente ou tomam o precursor do oxalato. O mercado oferece oportunidades em ambos os aspetos, seja para fazer uma dieta pobre em oxalato ou, por outro lado, espera-se que a dificuldade de manter uma dieta baixa em oxalato atue como uma oportunidade para o crescimento do mercado de medicamentos para a hiperoxalúria secundária . The renal replacement therapy is the next step after patient ignores the medication and other nutritional products which will significantly affect the product usage for medicinal treatment and lead to increased demand of renal replacement therapy which is expected to act as a challenge for the secondary hyperoxaluria drug market crescimento.
O relatório secundário do mercado de medicamentos para a hiperoxalúria fornece detalhes da quota de mercado, novos desenvolvimentos e análise do pipeline de produtos, impacto dos participantes do mercado doméstico e localizado, analisa as oportunidades em termos de bolsas de receitas emergentes, alterações nas regulamentações do mercado, aprovações de produtos, decisões estratégicas, lançamentos de produtos , expansões geográficas e inovações tecnológicas no mercado. Para compreender a análise e o cenário do mercado contacte-nos para um Analyst Brief, a nossa equipa irá ajudá-lo a criar uma solução de impacto na receita para atingir o objetivo desejado.
Âmbito do mercado de medicamentos para a hiperoxalúria secundária e dimensão do mercado
O mercado secundário de medicamentos para a hiperoxalúria está categorizado em cinco segmentos notáveis que se baseiam no tipo, tipo de medicamento, tipo de população, utilizador final e canal de distribuição. O crescimento entre segmentos ajuda-o a analisar os nichos de crescimento e as estratégias para abordar o mercado e determinar as suas principais áreas de aplicação e a diferença nos seus mercados-alvo.
- On the basis of type, the secondary hyperoxaluria drug market is segmented into reloxaliase, thiazide diuretics and supplements. In 2021, supplements segment is dominating in the secondary hyperoxaluria drug market as there is no targeted therapy available. However, some products are in the clinical trials and are expected to come to interstate commerce in near future. So management of the disease is done through supplements and dietary restrictions. Calcium supplements, magnesium supplements and other supplements serve as primary line of treatment along with dietary restrictions, fluid intake and probiotics which are used to maintain the gut flora.
- On the basis of drug type, the secondary hyperoxaluria drug market is segmented into prescription and over the counter. In 2021, over the counter segment is dominating in the secondary hyperoxaluria drug market as among all the products available for the treatment are generally supplements. After the successful diagnosis of the disease, the treatments suggested by physicians are available over the counter and a prescription is not necessary for these supplements to be consumed with regular diet owing to the reason for over the counter to dominate in the secondary hyperoxaluria drug market.
- On the basis of population type, the secondary hyperoxaluria drug market is segmented into children and adults. In 2021, adults segment is dominating in the secondary hyperoxaluria drug market as the diagnosis for secondary hyperoxaluria adults is usually carried out for indications of kidney stone and high oxalate excretion in the urine along with UTI. The prevalence of kidney stones is uncommon in children and the number of cases for the disease is comparatively very low when compared with adults.
- On the basis of end user, the secondary hyperoxaluria drug market is segmented into hospitals, specialty clinics, home healthcare and others. In 2021, home healthcare segment is dominating in the secondary hyperoxaluria drug market owing to the fact that the current treatment comprises of supplements and thiazide diuretics. These treatment products are taken by patients at home without the help of any medical professional and supervision hence dominating the segment of the secondary hyperoxaluria drug market.
- On the basis of distribution channel, the secondary hyperoxaluria drug market is segmented into hospital pharmacies, retail pharmacies, online pharmacies and others. In 2021, retail pharmacies segment is dominating in the secondary hyperoxaluria drug market as the numbers of these pharmacies are very high and increasing with year passing. They cater to majority of patients for buying drugs in traditional consumer purchase style. Moreover, retail pharmacies are focusing on broadening their services for better customer service.
Secondary Hyperoxaluria Drug Market Country Level Analysis
The secondary hyperoxaluria drug market is analysed and market size information is provided by the country, type, drug type, population type, end user and distribution channel as referenced above.
The countries covered in the secondary hyperoxaluria drug market report are the U.S., Canada and Mexico.
North America region holds the majority of the share in the secondary hyperoxaluria drug market due to high diagnosis and treatment rate. The U.S. expected to dominate in the North America market due to rising awareness regarding secondary hyperoxaluria.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Difficulty in Maintaining Low Oxalate Diet and Regulatory Support for Approval are Creating new Opportunities in the Secondary Hyperoxaluria Drug Market.
Secondary hyperoxaluria drug market also provides you with detailed market analysis for every country growth in particular industry with secondary hyperoxaluria drug product sales, impact of advancement in the secondary hyperoxaluria drug and changes in regulatory scenarios with their support for the secondary hyperoxaluria drug market. The data is available for historic period 2011 to 2019.
Competitive Landscape and Secondary Hyperoxaluria Drug Market Share Analysis
Secondary hyperoxaluria drug market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to secondary hyperoxaluria drug market.
The major companies providing secondary hyperoxaluria drug market are GlaxoSmithKline plc, Bayer AG, Pharmavite, Solgar Inc., Mission Pharmacal Company, Allena Pharmaceuticals, Inc., Celebrate Vitamins, Entring, LLC, OxThera, Renew Life Formulas, Inc., Synlogic, TIENS, Amway Corp., Infinitus , Now Foods, Nature's Bounty, Renew Life Formulas, Inc. among others. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
Muitos lançamentos de produtos e acordos são também iniciados pelas empresas de todo o mundo, que também estão a acelerar o mercado secundário de medicamentos para a hiperoxalúria.
Por exemplo,
- Em setembro de 2020, a Allena Pharmaceuticals, Inc. anunciou que assinou um acordo financeiro estratégico com a Pontifax Ventures, uma empresa líder em investimentos em ciências da vida, no valor de 25 milhões de dólares. Esta quantidade está a ser utilizada para a investigação sobre a Reloxaliase e a ALLN-346 e para desenvolver novos agentes terapêuticos para doenças metabólicas e renais.
- Em dezembro de 2020, a Synlogic apresentou detalhes sobre o seu potencial candidato a ensaio clínico para a hiperoxalúria entérica SYNB8802 na 3ª conferência internacional sobre engenharia de microbiomas do Instituto Americano de Engenheiros Químicos. O SYNB8802 encontra-se atualmente na fase 1 dos ensaios clínicos para a hiperoxalúria entérica. A empresa está a apresentar o desenvolvimento relacionado com este candidato que ajudará a aumentar o interesse e a abordagem da empresa em relação à hiperoxalúria.
A colaboração, as joint ventures e outras estratégias dos participantes do mercado estão a melhorar o mercado da empresa no mercado de medicamentos para a hiperoxalúria secundária, o que também oferece o benefício para as organizações melhorarem as suas ofertas de medicamentos para a hiperoxalúria secundária.
SKU-
Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo
- Painel interativo de análise de dados
- Painel de análise da empresa para oportunidades de elevado potencial de crescimento
- Acesso de analista de pesquisa para personalização e customização. consultas
- Análise da concorrência com painel interativo
- Últimas notícias, atualizações e atualizações Análise de tendências
- Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Índice
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PIPELINE ANALYSIS
5 REGULATORY SCENARIO OF NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET
5.1 REGULATORY FRAMEWORK FOR PROBIOTICS
5.2 REGULATORY FRAMEWORK FOR EUROPE
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 TARGETED TREATMENT FOR SECONDARY HYPEROXALURIA IS IN HIGH DEMAND
6.1.2 R&D INVESTMENT IN COMPANIES FOCUSING ON DRUG DEVELOPEMENT
6.1.3 LOW DIETARY AWARENESS IN UPPER SOCIO-ECONOMIC SOCIETY
6.1.4 INCREASED NUMBER OF CASES FOR SECONDARY HYPEROXALURIA
6.1.5 LOSS OF OXALOBACTER FORMIGENES
6.2 RESTRAINTS
6.2.1 LIMITED OPERATING REVENUE
6.2.2 HIGH COST OF TREATING SECONDARY HYPEROXALURIA
6.2.3 LIMITED SECONDARY THERAPEUTICS OPTION FOR TREATMENT
6.3 OPPORTUNITIES
6.3.1 DIFFICULTY IN MAINTAINING LOW OXALATE DIET
6.3.2 INCREASING NUMBER OF BARIATRIC SURGERY
6.3.3 REGULATORY SUPPORT FOR APPROVAL
6.3.4 RISING DISPOSABLE INCOME
6.4 CHALLENGES
6.4.1 DELAY IN DIAGNOSIS OF DISEASE LEADING TO NEED FOR RENAL REPLACEMENT
6.4.2 INCREASE FITNESS AWARENESS AMONG PEOPLE
6.4.3 INCREASE FLUID INTAKE AS A PREVENTIVE MEASURES
7 COVID-19 IMPACT ON NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET
7.1 OVERVIEW
7.2 PRICE IMPACT
7.3 IMPACT ON DEMAND
7.4 IMPACT ON SUPPLY CHAIN
7.5 STRATEGIC DECISIONS FOR MANUFACTURERS
7.6 CONCLUSION
8 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE
8.1 OVERVIEW
8.2 SUPPLEMENTS
8.2.1 OXALATE BINDING AGENTS
8.2.1.1 CALCIUM SUPPLEMENTS
8.2.1.2 MAGNESIUM SUPPLEMENTS
8.2.1.3 OTHERS
8.2.2 CITRATE SUPPLEMENTS
8.2.3 PYRIDOXINE SUPPLEMENTS
8.2.4 PROBIOTICS
8.3 THIAZIDE DIURETICS
8.4 RELOXALIASE
9 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET, BY DRUG TYPE
9.1 OVERVIEW
9.2 OVER THE COUNTER
9.3 PRESCRIPTION
10 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET, BY POPULATION TYPE
10.1 OVERVIEW
10.2 ADULTS
10.3 CHILDREN
11 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET, BY END USER
11.1 OVERVIEW
11.2 HOME HEALTHCARE
11.3 HOSPITALS
11.4 SPECIALTY CLINICS
11.5 OTHERS
12 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 RETAIL PHARMACIES
12.3 HOSPITAL PHARMACIES
12.4 ONLINE PHARMACIES
12.5 OTHERS
13 NORTH AMERICA SECONDARY HYPEROXLURIA DRUG MARKET, BY GEOGRAPHY
13.1 NORTH AMERICA
13.1.1 U.S.
13.1.2 CANADA
13.1.3 MEXICO
14 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
15 COMPANY PROFILE
15.1 NESTLE
15.1.1 COMPANY SNAPSHOT
15.1.2 REVENUE ANALYSIS
15.1.3 COMPANY SHARE ANALYSIS
15.1.4 PRODUCT PORTFOLIO
15.1.5 RECENT DEVELOPMENTS
15.2 GLAXOSMITHKLINE PLC
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 COMPANY SHARE ANALYSIS
15.2.4 PRODUCT PORTFOLIO
15.2.5 RECENT DEVELOPMENT
15.3 BAYER AG
15.3.1 COMPANY SNAPSHOT
15.3.2 REVENUE ANALYSIS
15.3.3 COMPANY SHARE ANALYSIS
15.3.4 PRODUCT PORTFOLIO
15.3.5 RECENT DEVELOPMENTS
15.4 NOW FOODS
15.4.1 COMPANY SNAPSHOT
15.4.2 COMPANY SHARE ANALYSIS
15.4.3 PRODUCT PORTFOLIO
15.4.4 RECENT DEVELOPMENTS
15.5 SOLGAR INC.
15.5.1 COMPANY SNAPSHOT
15.5.2 COMPANY SHARE ANALYSIS
15.5.3 PRODUCT PORTFOLIO
15.5.4 RECENT DEVELOPMENT
15.6 PHARMAVITE
15.6.1 COMPANY SNAPSHOT
15.6.2 PRODUCT PORTFOLIO
15.6.3 RECENT DEVELOPMENTS
15.7 INFINITUS (CHINA)
15.7.1 COMPANY SNAPSHOT
15.7.2 PRODUCT PORTFOLIO
15.7.3 RECENT DEVELOPMENTS
15.8 MISSION PHARMACAL COMPANY
15.8.1 COMPANY SNAPSHOT
15.8.2 PRODUCT PORTFOLIO
15.8.3 .RECENT DEVELOPMENT
15.9 OYSTER SHELL
15.9.1 COMPANY SNAPSHOT
15.9.2 PRODUCT PORTFOLIO
15.9.3 RECENT DEVELOPMENT
15.1 ALLENA PHARMACEUTICALS, INC.
15.10.1 COMPANY SNAPSHOT
15.10.2 PRODUCT PORTFOLIO
15.10.3 RECENT DEVELOPMENTS
15.11 AMWAY CORP.
15.11.1 COMPANY SNAPSHOT
15.11.2 PRODUCT PORTFOLIO
15.11.3 RECENT DEVELOPMENTS
15.12 CELEBRATE VITAMINS
15.12.1 COMPANY SNAPSHOT
15.12.2 PRODUCT PORTFOLIO
15.12.3 RECENT DEVELOPMENTS
15.13 ENTRING, LLC
15.13.1 COMPANY SNAPSHOT
15.13.2 PRODUCT PORTFOLIO
15.13.3 RECENT DEVELOPMENTS
15.14 NATURE’S BOUNTY
15.14.1 COMPANY SNAPSHOT
15.14.2 PRODUCT PORTFOLIO
15.14.3 RECENT DEVELOPMENT
15.15 OXTHERA
15.15.1 COMPANY SNAPSHOT
15.15.2 PRODUCT PORTFOLIO
15.15.3 RECENT DEVELOPMENT
15.16 RENEW LIFE FORMULAS, INC.
15.16.1 COMPANY SNAPSHOT
15.16.2 PRODUCT PORTFOLIO
15.16.3 RECENT DEVELOPMENTS
15.17 SYNLOGIC
15.17.1 COMPANY SNAPSHOT
15.17.2 REVENUE ANALYSIS
15.17.3 PRODUCT PORTFOLIO
15.17.4 RECENT DEVELOPMENTS
15.18 TIENS
15.18.1 COMPANY SNAPSHOT
15.18.2 PRODUCT PORTFOLIO
15.18.3 RECENT DEVELOPMENTS
16 QUESTIONNAIRE
17 RELATED REPORTS
Lista de Tabela
LIST OF TABLES
TABLE 1 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET, PIPELINE ANALYSIS
TABLE 2 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: BY TYPE, 2019-2028 (USD MILLION)
TABLE 3 NORTH AMERICA SUPPLEMENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 4 NORTH AMERICA SUPPLEMENTS IN SECONDARY HYPEROXALURIA DRUG MARKET: BY TYPE, 2019-2028 (USD MILLION)
TABLE 5 NORTH AMERICA OXALATE BINDING AGENTS IN SECONDARY HYPEROXALURIA DRUG MARKET: BY TYPE, 2019-2028 (USD MILLION)
TABLE 6 NORTH AMERICA THIAZIDE DIURETICS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 7 NORTH AMERICA RELOXALIASE IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 8 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 9 NORTH AMERICA OVER THE COUNTER IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 10 NORTH AMERICA PRESCRIPTION IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 11 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 12 NORTH AMERICA ADULTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 13 NORTH AMERICA CHILDREN IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 14 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 15 NORTH AMERICA HOME HEALTHCARE IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 16 NORTH AMERICA HOSPITALS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 17 NORTH AMERICA SPECIALTY CLINICS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 18 NORTH AMERICA OTHERS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 19 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 20 NORTH AMERICA RETAIL PHARMACIES IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 21 NORTH AMERICA HOSPITAL PHARMACIES IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 22 NORTH AMERICA ONLINE PHARMACIES IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 23 NORTH AMERICA OTHERS PHARMACIES IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 24 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 25 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 26 NORTH AMERICA SUPPLEMENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 27 NORTH AMERICA OXALATE-BINDING AGENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 28 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 29 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 30 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 31 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 32 U.S. SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 33 U.S. SUPPLEMENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 34 U.S. OXALATE-BINDING AGENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 35 U.S. SECONDARY HYPEROXALURIA DRUG MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 36 U.S. SECONDARY HYPEROXALURIA DRUG MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 37 U.S. SECONDARY HYPEROXALURIA DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 38 U.S. SECONDARY HYPEROXALURIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 39 CANADA SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 40 CANADA SUPPLEMENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 41 CANADA OXALATE-BINDING AGENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 42 CANADA SECONDARY HYPEROXALURIA DRUG MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 43 CANADA SECONDARY HYPEROXALURIA DRUG MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 44 CANADA SECONDARY HYPEROXALURIA DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 45 CANADA SECONDARY HYPEROXALURIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 46 MEXICO SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 47 MEXICO SUPPLEMENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 48 MEXICO OXALATE-BINDING AGENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 49 MEXICO SECONDARY HYPEROXALURIA DRUG MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 50 MEXICO SECONDARY HYPEROXALURIA DRUG MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 51 MEXICO SECONDARY HYPEROXALURIA DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 52 MEXICO SECONDARY HYPEROXALURIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
Lista de Figura
LIST OF FIGURES
FIGURE 1 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: MULTIVARIATE MODELLING
FIGURE 7 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: DBMR MARKET POSITION GRID
FIGURE 9 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: MARKET END USER COVERAGE GRID
FIGURE 10 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: SEGMENTATION
FIGURE 12 LOW DIETARY AWARENESS IN UPPER SOCIO-ECONOMIC SOCIETY IS EXPECTED TO DRIVE THE NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 13 SUPPLEMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET IN 2021 & 2028
FIGURE 14 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET AND EUROPE IS ESTIMATED TO BE GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 15 REGULATORY FRAMEWORK FOR PROBIOTICS
FIGURE 16 DRIVERS, RESTRAINT, OPPORTUNITIES AND CHALLENGE OF NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET
FIGURE 17 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: BY TYPE, 2020
FIGURE 18 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: BY TYPE, 2020-2028 (USD MILLION)
FIGURE 19 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: BY TYPE, CAGR (2021-2028)
FIGURE 20 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: BY TYPE, LIFELINE CURVE
FIGURE 21 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: BY DRUG TYPE, 2020
FIGURE 22 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: BY DRUGS CLASS, 2020-2028 (USD MILLION)
FIGURE 23 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: BY DRUG TYPE, CAGR (2021-2028)
FIGURE 24 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 25 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: BY POPULATION TYPE, 2020
FIGURE 26 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: BY POPULATION TYPE, 2020-2028 (USD MILLION)
FIGURE 27 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: BY POPULATION TYPE, CAGR (2021-2028)
FIGURE 28 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: BY POPULATION TYPE, LIFELINE CURVE
FIGURE 29 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: BY END USER, 2020
FIGURE 30 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: BY END USER, 2020-2028 (USD MILLION)
FIGURE 31 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: BY END USER, CAGR (2021-2028)
FIGURE 32 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: BY END USER, LIFELINE CURVE
FIGURE 33 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 34 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)
FIGURE 35 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 36 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 37 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: SNAPSHOT (2020)
FIGURE 38 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: BY COUNTRY (2020)
FIGURE 39 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: BY COUNTRY (2021 & 2028)
FIGURE 40 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: BY COUNTRY (2021 & 2028)
FIGURE 41 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: BY TYPE (2021-2028)
FIGURE 42 NORTH AMERICA SECONDARY HYPEROXALURIA DRUG MARKET: COMPANY SHARE 2020 (%)
Metodologia de Investigação
A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.
A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.
Personalização disponível
A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.
